logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investor Relations
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

News

    • 14 DEC 2020

    PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product

    LAGUNA HILLS, CA, December 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced additional physical parameter testing of its CypCaps® product for pancreatic cancer, in line with the recommendations

    Read more →
    • Posted in
    • News
    • 02 DEC 2020

    PharmaCyte Biotech Successfully Completes 9-Month Stability Study

    LAGUNA HILLS, CA, December 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration

    Read more →
    • Posted in
    • News
    • 04 NOV 2020

    PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) with respect to its Investigational New Drug Application (IND).

    Read more →
    • Posted in
    • News
    • 02 OCT 2020

    PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U. S. FDA

    LAGUNA HILLS, CA, October 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the company’s submitted Investigational New Drug

    Read more →
    • Posted in
    • News
    • 23 SEP 2020

    PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

    LAGUNA HILLS, CA, September 23, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it continues to engage with the U.S. Food and Drug Administration (FDA) during its 30-day comment period regarding

    Read more →
    • Posted in
    • News
    • 14 SEP 2020

    PharmaCyte Biotech Successfully Completes Six-Month Stability Study

    LAGUNA HILLS, CA, September 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the six-month product stability testing that is required by the U.S. Food and Drug

    Read more →
    • Posted in
    • News
    • 08 SEP 2020

    PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test

    LAGUNA HILLS, CA, September 8, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the second Container Closure Integrity (CCI) test that is required by the U.S. Food

    Read more →
    • Posted in
    • News
    • 02 SEP 2020

    PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

    LAGUNA HILLS, CA, September 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for

    Read more →
    • Posted in
    • News
    • 10 AUG 2020

    PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer

    LAGUNA HILLS, CA, August 10, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed José L. Iglesias M.D. as Consulting Chief

    Read more →
    • Posted in
    • News
    • 05 AUG 2020

    FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy

    LAGUNA HILLS, CA, August 5, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Drug Master File (DMF) that its partner, Austrianova, filed with the U.S. Food and Drug Administration (FDA) has

    Read more →
    • Posted in
    • News
  • 1
  • 2
  • 3
  • ›
  • »

Contact Us

PharmaCyte Biotech Inc.
23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92653
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS

Latest News

  • PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product 2020-12-14T08:45:39-0500
  • PharmaCyte Biotech Successfully Completes 9-Month Stability Study 2020-12-02T09:00:57-0500

Subscribe to Our Mailing List

* indicates required
Email Format